Company intelligence / Profile preview

RapidAI

Golden, Colorado, United Statesrapidai.com ↗

Ownership: Private
Development stage: Other

Overview

RapidAI’s clinical AI platform has been validated in over 25 clinical trials and more than 700 publications. Its technology was instrumental in expanding the stroke treatment window from 6 to 24 hours based on landmark DAWN and DEFUSE 3 trials. The company’s products are FDA-cleared for multiple indications and are used at over 2,250 hospitals across more than 100 countries. Recent studies show its LVO detection outperforms competitors such as Viz.ai.

Therapeutic areas: NeurologyCardiovascularOther
Modalities: Device (medical imaging software)Non-pharmacological therapy (clinical decision support software)
Industry: Medical Imaging

Partnerships

Not specifically listed in search results; likely partnerships with major hospital systems worldwide.

Beyond the preview

Go deeper on RapidAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RapidAI.

Explore the full profile